Rutledge Cancer Foundation Awards $1.5 Million Grant To Fuel Groundbreaking Research to Advance New Treatments for Ewing Sarcoma

The Rutledge Cancer Foundation has awarded a landmark $1.5 million ACES (Accelerating Cures for Ewing Sarcoma) grant to support pioneering research into new treatments for Ewing sarcoma. This major funding initiative aims to bridge the gap between initial laboratory discoveries and clinical trials, speeding up the development of targeted therapies for patients facing this aggressive pediatric and young adult bone cancer. By directly backing innovative scientists and multi-institutional collaborations, the grant targets the root genetic drivers of Ewing sarcoma to overcome drug resistance and improve overall survival rates.

This $1.5 million grant acts as a powerful financial boost to turn promising scientific ideas into actual, life-saving medicines for kids and young adults with Ewing sarcoma. Standard treatments for this rare bone cancer haven’t changed significantly in decades, often leaving patients with harsh side effects and few options if the disease returns. By funding cutting-edge lab research, the foundation is helping doctors build smarter, more effective treatments that can precisely destroy cancer cells while sparing healthy tissue.

Read the full article